No results were found for your search. Please adjust your search term or broaden your search criteria.
Still can't find what you are looking for? We can prepare Custom Research for you.
The Kallikrein Inhibitor market is a subset of the Immune Disorders Drugs market. Kallikrein Inhibitors are a type of drug used to treat a variety of immune disorders, including allergies, asthma, and autoimmune diseases. These drugs work by blocking the activity of kallikrein, an enzyme that plays a role in inflammation. Kallikrein Inhibitors are typically administered orally or intravenously, and can be used in combination with other drugs to treat more severe cases.
Kallikrein Inhibitors are becoming increasingly popular due to their effectiveness in treating a wide range of immune disorders. They are also relatively safe, with few side effects. As a result, the Kallikrein Inhibitor market is expected to continue to grow in the coming years.
Some companies in the Kallikrein Inhibitor market include AbbVie, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Merck, Novartis, Pfizer, and Sanofi. Show Less Read more
